Abstract
Metoclopramide, by its action on the inferior esophageal sphincter, and on the motility of the lower esophagus, decreases the incidence of gastroesophageal reflux. It is therefore logical to think that this substance may permit reduction in the intake of antacids.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
McCallum RW et al. (1977) A controlled trial of Metoclopramide in symptomatic gastroesophageal reflux. New Engl J Med 296, 7:354–357
Bright-Asare P, El Bassoussi M (1980) Cimetidine, Metoclopramide or placebo in the treatment of symptomatic gastroesophageal reflux. J Clin Gastroenterology, 149–156
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1989 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Cargill, G. (1989). Doesn’t metoclopramide allow a significant decrease in antacid consumption?. In: Giuli, R., McCallum, R.W. (eds) Benign Lesions of the Esophagus and Cancer. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-73055-9_70
Download citation
DOI: https://doi.org/10.1007/978-3-642-73055-9_70
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-73057-3
Online ISBN: 978-3-642-73055-9
eBook Packages: Springer Book Archive